A phase II study of HyperAcute-lung cancer vaccine in subjects with advanced non-small cell lung cancer who responded to first line platinum-doublet treatment.

Trial Profile

A phase II study of HyperAcute-lung cancer vaccine in subjects with advanced non-small cell lung cancer who responded to first line platinum-doublet treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Tergenpumatucel-L (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 21 May 2013 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 27 May 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top